Physician profile
Joseph Jacko
NPI 1730185844
$8,831.49
in general payments reported to CMS, 2019-2025
44 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,418 · 2020: $2,097 · 2021: $2,296 · 2022: $1,721 · 2023: $91.87 · 2024: $101 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295 · Education: $5.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $294.55 |
| Education | $5.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,663.37 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $813.57 | 2019-2022 | |
| Abbvie INC. | $712.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $690.95 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $670.68 | 2019-2022 | |
| Amarin Pharma, INC. | $578.74 | 2019-2021 | |
| Lilly USA, LLC | $506.74 | 2019-2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $382.58 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $349.28 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.24 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $202.18 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.23 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $166.65 | 2019-2022 | |
| Esperion Therapeutics, INC. | $163.71 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $157.65 | 2020-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Jacko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.